162. 類天疱瘡(後天性表皮水疱症を含む。) Pemphigoid Clinical trials / Disease details


臨床試験数 : 83 薬物数 : 128 - (DrugBank : 51) / 標的遺伝子数 : 33 - 標的パスウェイ数 : 142

  
7 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2020-000287-32-GR
(EUCTR)
04/11/202113/09/2021A study to investigate the use of benralizumab in patients with bullous pemphigoidA Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Investigate the Use of Benralizumab as a Treatment Option for Patients with Bullous Pemphigoid (FJORD) - FJORD Bullous Pemphigoid
MedDRA version: 21.1;Level: LLT;Classification code 10006567;Term: Bullous pemphigoid;System Organ Class: 100000004858;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
Trade Name: Fasenra
Product Name: benralizumab
Product Code: MEDI-563
INN or Proposed INN: benralizumab
Other descriptive name: benralizumab
AstraZeneca ABNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
120Phase 3France;United States;Greece;Spain;Australia;Bulgaria;Israel;Germany;Italy;Japan;China
2EUCTR2020-000287-32-DE
(EUCTR)
12/04/202116/10/2020A study to investigate the use of benralizumab in patients with bullous pemphigoidA Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Investigate the Use of Benralizumab as a Treatment Option for Patients with Bullous Pemphigoid (FJORD) - FJORD Bullous Pemphigoid
MedDRA version: 21.1;Level: LLT;Classification code 10006567;Term: Bullous pemphigoid;System Organ Class: 100000004858;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
Trade Name: Fasenra
Product Name: benralizumab
Product Code: MEDI-563
INN or Proposed INN: benralizumab
Other descriptive name: benralizumab
AstraZeneca ABNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
120Phase 3United States;France;Greece;Spain;Australia;Israel;Bulgaria;Germany;Japan;Italy;China
3NCT04612790
(ClinicalTrials.gov)
March 31, 202112/10/2020A Study to Investigate the Use of Benralizumab in Patients With Bullous Pemphigoid.A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Investigate the Use of Benralizumab as a Treatment Option for Patients With Bullous Pemphigoid (FJORD)Bullous PemphigoidBiological: Benralizumab;Biological: PlaceboAstraZenecaNULLRecruiting18 Years130 YearsAll120Phase 3United States;Australia;Bulgaria;China;France;Germany;Greece;Israel;Italy;Japan;Spain
4JPRN-jRCT2071210014
26/03/202126/04/2021A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Investigate the Use of Benralizumab as a Treatment Option for Patients With Bullous Pemphigoid.The purpose of this study is to investigate the use of benralizumab is effective in the treatment of patients symptomatic Bullous Pemphigoid (BP). - FJORD Bullous PemphigoidThis study is designed to assess the efficacy and safety of a benralizumab 60 mg loading dose followed by repeat dosing of subcutaneously (SC) administered benralizumab 30 mg versus placebo in adult participants with symptomatic BP.

Following screening, about 120 eligible participants will be randomized 1:1 to receive either benralizumab or placebo.

Double-blind treatment period (0w-36w): In the benralizumab group, 60 mg initially and 30 mg thereafter are subcutaneously administered every 4 weeks. In the placebo group, placebo is subcutaneously administered every 4 weeks.

Open-label extension period (36w-): All participants who complete the double-blind dosing period will be given the option of receiving benralizumab 30 mg subcutaneously every 4 weeks.
Hibi KazushigeNULLRecruiting>= 18age oldNot applicableBoth12Phase 3United States;Australia;Bulgaria;France;Germany;Israel;Italy;Spain;Japan
5EUCTR2020-000287-32-FR
(EUCTR)
09/02/202103/11/2020A study to investigate the use of benralizumab in patients with bullous pemphigoidA Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Investigate the Use of Benralizumab as a Treatment Option for Patients with Bullous Pemphigoid - FJORD Bullous Pemphigoid
MedDRA version: 21.1;Level: LLT;Classification code 10006567;Term: Bullous pemphigoid;System Organ Class: 100000004858;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
Product Name: benralizumab
Product Code: MEDI-563
INN or Proposed INN: benralizumab
Other descriptive name: benralizumab
AstraZeneca ABNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
120Phase 3United States;France;Spain;Australia;Israel;Bulgaria;Germany;Japan;Italy
6EUCTR2020-000287-32-IT
(EUCTR)
22/01/202124/05/2021A study to investigate the use of benralizumab in patients with bullous pemphigoidA Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Investigate the Use of Benralizumab as a Treatment Option for Patients with Bullous Pemphigoid - FJORD Bullous Pemphigoid
MedDRA version: 21.1;Level: LLT;Classification code 10006567;Term: Bullous pemphigoid;System Organ Class: 100000004858;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
Product Name: Benralizumab
Product Code: [MEDI-563]
INN or Proposed INN: Benralizumab
ASTRAZENECA ABNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
120Phase 3France;United States;Spain;Australia;Bulgaria;Israel;Germany;Japan;Italy
7EUCTR2020-000287-32-BG
(EUCTR)
02/12/202006/10/2020A study to investigate the use of benralizumab in patients with bullous pemphigoidA Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Investigate the Use of Benralizumab as a Treatment Option for Patients with Bullous Pemphigoid (FJORD) - FJORD Bullous Pemphigoid
MedDRA version: 21.1;Level: LLT;Classification code 10006567;Term: Bullous pemphigoid;System Organ Class: 100000004858;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
Trade Name: Fasenra
Product Name: benralizumab
Product Code: MEDI-563
INN or Proposed INN: benralizumab
Other descriptive name: benralizumab
AstraZeneca ABNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
120Phase 3France;United States;Greece;Spain;Australia;Israel;Bulgaria;Germany;Italy;Japan;China